Anti-Müllerian hormone, or AMH, has moved from fertility clinics into midlife wellness marketing. The pitch is seductive: one blood test can tell you how many eggs remain and when menopause will arrive. The biology is real. AMH does reflect ovarian reserve. The leap from a laboratory value to a personal countdown is where the evidence thins, and where women’s midlife health has been poorly served by oversimplified numbers.
What AMH actually measures
AMH is produced by small follicles in the ovary. In reproductive-age women, higher levels generally mean more remaining follicles; lower levels mean fewer. Unlike oestrogen, which fluctuates across the cycle, AMH is relatively stable, which is why fertility clinics have used it for years to estimate how a woman might respond to ovarian stimulation.
That stability is useful in one clinical lane and misleading in another. AMH counts follicles. It does not measure egg quality, cycle regularity, hot flushes, sleep disruption, brain fog, libido, bone density, or cardiovascular risk. Menopause is a hormonal transition with symptoms and health consequences; it is not simply the day the last follicle disappears.
ACOG’s Committee Opinion on AMH in women not seeking fertility care describes serum AMH as a useful measure of quantitative ovarian reserve, whilst warning that it should not be used as a broad screening tool for fertility counselling in low-risk women. That distinction matters because many direct-to-consumer panels collapse it.
Why the test is appearing outside fertility clinics
Two forces are converging. First, women are seeking earlier clarity about perimenopause, family planning, and surgical decisions. Second, laboratories and wellness brands have packaged AMH as a longevity or menopause-timing biomarker, often alongside FSH, oestradiol, and thyroid tests in a single panel.
The marketing language often implies precision: “your ovarian age”, “years until menopause”, “time to act”. Clinically, the honest version is probabilistic. A low AMH in a 47-year-old suggests menopause may be nearer than in a peer with a higher value. It does not hand you a calendar date, and it does not tell you whether hormone therapy, contraception, fertility treatment, or simple watchful waiting is appropriate.
Women’s hormonal transitions have been under-studied for decades relative to their impact on brain function, sleep, metabolism, and cardiovascular health. A single number cannot repair that evidence gap. It can, however, create false certainty at a life stage that already invites anxiety.
What the SWAN study added — and what it did not
The most influential recent work comes from the Study of Women’s Health Across the Nation (SWAN), a long-running US cohort following women through the menopausal transition. In a 2020 analysis published in the Journal of Clinical Endocrinology & Metabolism, researchers measured AMH and FSH serially in 1,537 women aged roughly 42 to 63 until they reached 12 months of amenorrhoea.
Using a more sensitive assay than many clinics had at the time, the team found that AMH predicted the final menstrual period better than FSH, especially over the next 24 months. Probabilities varied by age. For example, a woman under 48 with AMH below 10 pg/mL had roughly a 51% chance of reaching her final period within 12 months; at 51 or older, that probability rose to about 79%. Conversely, a woman with AMH above 100 pg/mL had a 90–97% chance of not reaching menopause within the next year, depending on age.
That is genuinely useful science. It is also narrower than the consumer version. The model works best in late reproductive age, when AMH is already falling, and it expresses risk as a probability band, not a guarantee. A 51% chance of menopause within a year is not the same as “menopause next autumn”.
The Endocrine Society’s summary of the findings noted that older methods could only narrow timing to about a four-year window. The newer assay tightened that window in research settings. Tightening a research window is not the same as validating every commercial kit sold online.
Why major guidelines remain cautious
Fertility medicine and general midlife care are not the same consultation. In 2019, the American College of Obstetricians and Gynaecologists issued its AMH committee opinion for women not seeking fertility care. The document reviews AMH as a predictor of future fertility and menopause, but it does not endorse routine AMH screening for women who are not trying to conceive and have no specific clinical indication.
The reasoning is practical. AMH can be low in a woman who still ovulates regularly, and “normal for age” ranges are not standardised across assays. A result that feels alarming may not change management if cycles are stable and pregnancy is not desired. A reassuring result does not rule out perimenopausal symptoms driven by progesterone decline, sleep disruption, thyroid disease, or stress.
For women under 45 with irregular periods or menopausal symptoms, clinicians may order blood tests as part of assessment. The NHS guidance on early or premature menopause explains that menopause before 45 — and especially before 40 — warrants medical review, sometimes including hormone testing, because bone and cardiovascular risk can rise when periods stop early. That is a different scenario from a healthy 43-year-old buying an AMH add-on out of curiosity.
Assay variation makes comparison hazardous
AMH is not measured on one universal scale. Different laboratories use different kits, reference ranges, and lower limits of detection. A value from a fertility clinic assay may not mean the same thing as a value from a wellness panel using another method. Some kits cannot detect the very low concentrations that matter most near menopause unless they use research-grade sensitivity.
This is why comparing results across time, unless done in the same laboratory with the same assay, is fragile. It is also why app-based “ovarian age” scores built on a single pinprick sample deserve scepticism. The SWAN probabilities were derived from a defined cohort, a specific ELISA, and repeated measurements over years — not from one cross-sectional result interpreted in isolation.
Readers who already have an AMH result should ask which assay was used, whether the sample was taken on any day of the cycle, and whether the reporting laboratory publishes age-specific reference intervals. Without that context, the number is difficult to interpret responsibly.
When AMH is genuinely informative
AMH is not useless. It is context-dependent. Fertility specialists use it to discuss expected response to IVF stimulation and to counsel women considering delayed childbearing. Endocrinologists and gynaecologists may use it when evaluating possible premature ovarian insufficiency, especially alongside FSH, oestradiol, cycle history, and symptoms.
It can also matter after cancer treatment. Chemotherapy and pelvic radiotherapy can deplete ovarian follicles; AMH may help characterise remaining reserve when pregnancy or hormone decisions are on the table. In those settings, the test is embedded in a clinical story, not sold as a standalone fortune-telling exercise.
Perimenopause is often discussed as a countdown to the last period. Many women experience it first as sleep fragmentation, mood change, memory lapses, joint pain, or heavier irregular bleeding — sometimes whilst cycles still look “normal” on paper. Oestrogen and progesterone fluctuate unevenly long before AMH bottoms out. Symptoms deserve clinical attention. Cycle pattern matters. AMH may add reserve information in selected cases. None of those layers replaces a careful history, thyroid assessment where appropriate, review of medications and sleep, and discussion about contraception needs, because ovulation can still occur even as AMH falls.
What AMH should not do is drive panic purchases of supplements, “hormone-balancing” protocols, or elective oocyte freezing in every woman with a below-average result. Oocyte freezing is a legitimate option for some people; it is also costly, invasive, and not a guaranteed hedge against later infertility. The decision belongs in shared medical counselling, not in a marketing funnel triggered by one lab line.
What this means in practice
- Treat AMH as an ovarian-reserve marker, not a menopause date, a brain-age score, or proof that symptoms are “hormonal”.
- If you are under 45 with irregular periods, hot flushes, night sweats, or suspected early menopause, see a clinician; blood tests may be appropriate as part of assessment, not as a solo answer.
- If you are considering pregnancy, fertility treatment, or egg freezing, ask a fertility specialist how AMH fits alongside age, cycle history, and antral follicle count.
- Ask which assay produced your result and avoid comparing values from different laboratories or home kits as if they were interchangeable.
- Do not start supplements, hormone creams, or private “optimisation” protocols based on a single AMH reading without medical review, especially if you have migraine with aura, thrombosis risk, breast cancer history, or unexplained bleeding.
- Keep using contraception in perimenopause until a clinician confirms menopause if pregnancy is not desired; AMH does not tell you whether you ovulated this month.
What we don’t know
We still lack randomised evidence that knowing your AMH in general midlife care improves long-term outcomes, quality of life, or decision quality for women not seeking fertility treatment. We also lack universal assay standardisation, which limits population screening.
Probabilities from cohort studies describe groups, not individuals. Genetics, smoking, BMI, autoimmune disease, prior surgery, and chemotherapy can all shift trajectories in ways a single AMH value does not capture. And women’s neurological and metabolic responses to the menopausal transition remain active research areas, not settled algorithms.
The honest conclusion is measured. AMH is one of the better blood markers we have for estimating how close the ovaries are to running low on recruitable follicles, especially in the late 40s and early 50s. It is not a permission slip for dread, delay, or DIY hormone experiments. In midlife, the question is rarely “what is my number?” It is “what problem am I trying to solve, and who will help me interpret the answer?”
Photo: Julia Koblitz on Unsplash.